Chief Business Officer · Foghorn Therapeutics Inc. (FHTX)

Anna Rivkin

FY2024 is the first fiscal year CompBrief holds for Anna Rivkin as a named executive officer of Foghorn Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$1,472,584

Salary $143,333Stock awards $0Bonus $135,000

3rd of 5 named executive officers at Foghorn Therapeutics by FY2024 total.

5 named officers on file for Foghorn Therapeutics, FY2024

Anna Rivkin’s pay file — $29

  • 1 fiscal year of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Foghorn Therapeutics’s whole pay program stands against its peers

  • Foghorn Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on FHTX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed May 5, 2025 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Anna Rivkin’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Anna Rivkin compensation by year

Foghorn Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Foghorn Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024
Salary$143,333
Bonus$135,000
Stock awards$0
Option awards$1,123,912
Non-equity incentive$48,733
Pension and deferred compensation$0
All other$21,606
Total$1,472,584

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Foghorn Therapeutics Inc. DEF 14A filed May 5, 2025, accession 0001193125-25-112091, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Foghorn Therapeutics Inc. filed document, accession 0001193125-25-112091. Every figure is read from that document and cited to the page and table it appears in. Filed May 5, 2025.

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
Option190,000—$7.85

Per the Outstanding Equity Awards at Fiscal Year-End table in Foghorn Therapeutics Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

1 Form 4 line since the FY2024 proxy (filed May 5, 2025)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-01-30Grant or award derivative—165,000$5.71165,000

The 1 most recent of 1 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Foghorn Therapeutics’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Kristian HumerChief Financial Officer$1,888,603
Adrian GottschalkPresident and Chief Executive Officer$1,559,562
Anna Rivkin · this pageChief Business Officer$1,472,584
Steven BellonChief Scientific Officer$902,212
Alfonso Quintas-CardamaChief Medical Officer$769,489

The full Foghorn Therapeutics compensation record

free company brief

This page is one person within Foghorn Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Foghorn Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Anna Rivkin's compensation dossier · One-time report. No refunds.